Exscientia Agrees to Acquisition by Recursion Pharmaceuticals

Exscientia Plc (EXAI) has released an update.

Exscientia plc, an England and Wales incorporated public limited company, has entered into a transaction agreement on August 8, 2024, with Recursion Pharmaceuticals, Inc. The agreement outlines the acquisition of Exscientia by Recursion Pharmaceuticals through a Scheme of Arrangement, which is considered fair and in the best interests of the shareholders by Exscientia’s board of directors.

For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.